ASND — Ascendis Pharma A/S

Ascendis Pharma (ASND) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: €214 million in Q3 2025, up from €103 million in Q2 2025.
  • Eurvipath Revenue: €143.1 million, reflecting strong growth.
  • Skytrofa Revenue: €50.7 million, with a 3% growth in demand.
  • Collaboration Revenue: €20 million, including a €13 million milestone related to Eurvipath.
• Operating Income: Positive operating profit of €11 million.
• R&D Expenses: Decreased to €66.9 million from €73.5 million in Q3 2024.
• SG&A Expenses: Increased to €113.4 million, reflecting global commercial expansion.
• Cash Position: €539 million in cash and cash equivalents, up from €494 million at the end of Q2 2025.

2. Strategic Updates and Business Highlights

• Eurvipath: Strong global launch with over 4,250 patients prescribed in the US. The company is expanding its reach within the endocrinology community and other physician groups.
• Skytrofa: Approved for both pediatric and adult growth hormone deficiency, with ongoing label expansions.
• TransCon CNP: Under priority review by the FDA with a PDUFA date of November 30, 2025. The company is optimistic about its potential to become a leading treatment for achondroplasia.
• Clinical Trials: Initiated a Phase 3 trial for Skytrofa and a trial for higher doses of Eurvipath.
• Partnerships: Continued collaboration with Taigen in Japan and other partners in various therapeutic areas.

3. Forward Guidance and Outlook

• Q4 2025 Expectations: Continued revenue growth driven by new patient enrollments and stable pricing for Eurvipath. Skytrofa is also expected to see growth from geographic and label expansions.
• Long-term Goals: Ascendis aims to achieve €5 billion or more in annual revenue by 2030, supported by ongoing product development and market expansion.

4. Bad News, Challenges, or Points of Concern

• Currency Headwinds: Notable foreign currency impacts on revenue, particularly for Eurvipath and Skytrofa.
• Approval Rates: Currently at around 70% for Eurvipath, with expectations for gradual improvement over time. The company acknowledges the challenge of increasing this rate further.
• Market Penetration: While there is significant room for growth in the hypoparathyroidism market, the company faces challenges in activating and educating patients about their conditions.

5. Notable Q&A Insights

• Patient Enrollment: Management expressed confidence in stable prescription rates for Eurvipath, with a strong foundation for future growth.
• Seasonality Concerns: Executives indicated minimal expected impact from seasonal factors in Q4, contrasting with previous concerns about Q3.
• Switching Strategies: There is anticipation of a significant number of patients switching from existing treatments to TransCon CNP, particularly in markets where current therapies are well established.
• Payer Approval Process: Improvements in the payer approval timeline were noted, with expectations for continued enhancements in the future.

Overall, Ascendis Pharma reported a strong quarter with positive financial metrics and strategic advancements, while also acknowledging challenges related to market penetration and currency fluctuations. The company remains optimistic about its growth trajectory and upcoming product approvals.